Terms: = Prostate cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Clinical Outcome
4 results:
1. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
Nie J; Zhang P; Liang C; Yu Y; Wang X
Free Radic Biol Med; 2023 Aug; 205():318-331. PubMed ID: 37355053
[TBL] [Abstract] [Full Text] [Related]
2. prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in prostate cancer.
Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
[TBL] [Abstract] [Full Text] [Related]
3. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
[TBL] [Abstract] [Full Text] [Related]